Projekt

XATOC – Xarelto + Acetylsalicylic Acid

Abgeschlossen - Rekrutierung – beendet · 2020 bis 2023

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen - Rekrutierung – beendet
Start
2020
Ende
2023
Finanzierungsart
Industrie
Studiendesign
Observational
Schlagwörter (Tags)
Xarelto vasc. sympt. PAD or CAD
Kurzbeschreibung/Zielsetzung

Treatment patterns and Outcomes across the disease Continuum in
patients with CAD and/or PAD

The study aims to collect real-world data on treatment
patterns and decision points for treatment in patients with
coronary artery disease (CAD) or symptomatic peripheral
artery disease (PAD) treated with rivaroxaban 2.5 mg [twice
a day (BID)] plus low-dose ASA (75-100 mg) [once a day
(OD)] for the prevention of atherothrombotic events in adult
patients at high risk of ischemic events, and to describe the
outcomes under this combination across the broad range of
patient risk profiles encountered in routine clinical practice